ÖZEN, S. Et Al. 2020. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. ANNALS OF THE RHEUMATIC DISEASES , vol.79, no.10 , 1362-1369.

ÖZEN, S., Ben-Cherit, E., Foeldvari, I., Amarilyo, G., Ozdogan, H., Vanderschueren, S., ... Marzan, K.(2020). Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. ANNALS OF THE RHEUMATIC DISEASES , vol.79, no.10, 1362-1369.

ÖZEN, SEZA Et Al. "Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial," ANNALS OF THE RHEUMATIC DISEASES , vol.79, no.10, 1362-1369, 2020

ÖZEN, SEZA Et Al. "Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial." ANNALS OF THE RHEUMATIC DISEASES , vol.79, no.10, pp.1362-1369, 2020

ÖZEN, S. Et Al. (2020) . "Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial." ANNALS OF THE RHEUMATIC DISEASES , vol.79, no.10, pp.1362-1369.

@article{article, author={SEZA ÖZEN Et Al. }, title={Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial}, journal={ANNALS OF THE RHEUMATIC DISEASES}, year=2020, pages={1362-1369} }